DENVER, December 20 /PRNewswire/ --

CQG, Inc., the premier charting, analytics, and trade routing platform for global electronically-traded futures markets, today announced the addition of the European Energy Exchange (EEX) to its growing list of direct trading connections.

CQG has connected its hosted trading gateways to EEX, giving customers the ability to trade the Second Period European Carbon contract. A full listing of commodities available for trading is listed on http://www.cqg.com.

"This is a step in our continued commitment to provide a complete trading solution to our growing energy and emissions customer base," said Shaun Downey, CQG's Senior Technical Analyst.

ABBOTT PARK, Illinois, December 20 /PRNewswire/ --

- In Clinical Trials, Patients Taking HUMIRA Saw Significant and Sustained Skin Clearance

SALT LAKE CITY, December 20 /PRNewswire/ --

Equis International, a wholly owned subsidiary of Reuters (LSE: RTR), announced an exclusive partnership with WIN Investing -- winner of the 2006-2007 Investment Training Solutions Provider of the Year award given by Britain Business Magazine.

Beginning in early 2008, WIN Investing will begin training students using MetaStock software in their stock market training courses. MetaStock employs technical analysis to help traders chart and analyze a variety of instruments and make more informed trading decisions.

DUBLIN, Ireland, December 20 /PRNewswire/ --

- PopCap.com Helps Reduce Holiday Stress

As if offering up family-friendly, stress-busting games wasn't enough, PopCap Games are going further to help beat Christmas stress by giving customers 50% off all games at http://www.popcap.com until January 3rd 2008. (i)

PopCap joined forces with the Stress Management Society (UK) in 2007 to prove their games' stress relieving properties. Neil Shah, Director, The Stress Management Society (http://www.stress.org.uk) says: "A study conducted by The Stress Management Society showed that playing puzzle games like a PopCap Game for as little as 5 minutes a day has stress relieving benefits."

COPENHAGEN, Denmark, December 20 /PRNewswire/ --

- Summary: Genmab's Partner, Roche has Initiated a Phase II study of R1507 for the Treatment of Sarcoma

Genmab A/S (OMX: GEN) announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma. The R1507 antibody was created by Genmab under the company's agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.

"R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that R1507 may offer an additional treatment option to sarcoma patients."

GAITHERSBURG, Maryland, December 20 /PRNewswire/ --

- Company also Establishes New Site Leadership Team at Cambridge Facility

Continuing the solidification of its role as the global biologics unit for AstraZeneca plc (AZ), MedImmune today announced that Andrew D. Skibo has joined the company as senior vice president, engineering and JoAnn Suzich, Ph.D., a 19-year veteran of the company, has been promoted to vice president, research and development, infectious disease. In addition, MedImmune announced that it has established a new site leadership team at its Cambridge facilities as a part of the plan to integrate the former Cambridge Antibody Technology (CAT) organization into AZ's new global biologics unit, functioning under the name MedImmune.